FIELD: medicine; pharmaceuticals.
SUBSTANCE: invention refers to pharmaceutical industry, namely to a composition for treating diseases and symptoms selected from lower urinary tract symptoms (LUTS), erectile dysfunction (ED), benign prostatic hyperplasia (BPH), urinary incontinence, hyperactive urinary bladder (HUB). Dosage formulation for oral administration, selected from a solid dosage form or soft gel for treating diseases and symptoms selected from: lower urinary tract symptoms (LUTS), erectile dysfunction (ED), benign prostatic hyperplasia (BPH), urinary incontinence, hyperactive urinary bladder (HUB) containing 250 mg to 500 mg of therapeutic composition containing powder of dried cranberries and additionally cranberry seeds or cranberry flour, where additional cranberry seeds or cranberry flour are present in the therapeutic composition in amount of 15 % to 25 % of the weight of the dried cranberry fruit powder. Method of treating or relieving lower urinary tract symptoms (LUTS) in a subject in need thereof, wherein said method comprises administering to the subject one dosage form for oral administration. Method of treating urinary incontinence in a subject in need thereof, wherein said method comprises administering to the subject a single dosage form for oral administration. Method of treating a hyperactive urinary bladder (HUB) condition in a subject in need thereof, wherein said method comprises administering to the subject one dosage form for oral administration. Method of treating or alleviating the symptoms of benign prostatic hyperplasia (BPH) in a subject in need thereof, wherein said method comprises administering to the subject a single dosage form for oral administration. Method of treating erectile dysfunction (ED) in a subject in need thereof, wherein said method comprises administering to a subject one dosage form for oral administration. Method of treating diseases and symptoms selected from lower urinary tract symptoms (LUTS), urinary incontinence, hyperactive urinary bladder (HUB), benign prostatic hyperplasia (BPH), erectile dysfunction (ED), in a subject in need thereof, wherein said method comprises administering an oral dosage form to a subject.
EFFECT: composition described above is effective for treating diseases and symptoms selected from lower urinary tract symptoms (LUTS), erectile dysfunction (ED), benign prostatic hyperplasia (BPH), urinary incontinence, hyperactive urinary bladder (HUB).
31 cl, 2 dwg, 9 tbl, 3 ex
